Premedication with 20 mg dexamethasone effectively prevents relapse of extensive skin rash associated with gemcitabine monotherapy.


Gemcitabine treatment is commonly associated with skin rash, with a reported incidence of 7%–30% [1–3]; however, there exists only one prior report describing the management of gemcitabine-associated rash in the English-language literature [1]. When an extensive skin rash develops, both the patient and physician may experience anxiety about continuing… (More)
DOI: 10.1093/annonc/mdp513


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.